Cancer drug developer Mersana Therapeutics (NASDAQ:MRSN) hit a 52-week low on Friday after sharing early clinical results from a Phase 1 trial for its lead candidate emiltatug ledadotin (Emi-Le ...
Hosted on MSN26d
Mersana therapeutics VP Mandelia sells $1,128 in stockCAMBRIDGE, MA—Mersana Therapeutics, Inc. (NASDAQ:MRSN) recently reported that Ashish Mandelia, the company's Vice President and Chief Accounting Officer, executed a sale of common stock.
Mersana Therapeutics, Inc. CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and ...
William Blair analyst Andy Hsieh last night initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating. The firm believes Mersana offers investors a risk/reward skewed to the ...
Wedbush reiterated their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report released on Friday morning,RTT News reports. They currently have a $ ...
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated ...
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback